Page last updated: 2024-08-18

pyrroles and Erythrocytosis

pyrroles has been researched along with Erythrocytosis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R	1
Boven, E; Broxterman, HJ; Haanen, JG; van den Eertwegh, AJ; van der Veldt, AA; Vroling, L	1
Gállego Pérez-Larraya, J; Reyes-Botero, G; Sanson, M	1
Aghakhani, N; Casadeval, N; Croisille, L; David, P; Eschwège, P; Gaudric, A; Hermine, O; Richard, S; Scigalla, P; Yvart, J	1

Trials

1 trial(s) available for pyrroles and Erythrocytosis

Article	Year
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Angiogenesis Inhibitors; Enzyme Inhibitors; Female; Hematocrit; Humans; Indoles; Kinetics; Male; Middle Aged; Polycythemia; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; von Hippel-Lindau Disease	2002

Article

Year

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.

Blood, 2002, May-15, Volume: 99, Issue:10

Topics: Adult; Angiogenesis Inhibitors; Enzyme Inhibitors; Female; Hematocrit; Humans; Indoles; Kinetics; Male; Middle Aged; Polycythemia; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; von Hippel-Lindau Disease

2002

Other Studies

3 other study(ies) available for pyrroles and Erythrocytosis

Article	Year
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-20, Volume: 26, Issue:24 Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib	2008
Sunitinib-induced hemoglobin changes are related to the dosing schedule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8 Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Hemoglobins; Humans; Indoles; Polycythemia; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2	2009
Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia. Journal of neuro-oncology, 2012, Volume: 107, Issue:2 Topics: Adult; Antineoplastic Agents; Brain; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Indoles; Magnetic Resonance Imaging; Male; Polycythemia; Pyrroles; Spinal Cord; Sunitinib	2012